CENTOGENE Contributes to Europe-Wide Efforts to Update Guidelines for Whole Genome Sequencing (WGS) in Rare Disease Diagnostics
May 23, 2022 06:30 ET
|
Centogene NV
Newly established WGS recommendations published in the European Journal of Human Genetics Collaborative initiative leverages CENTOGENE’s differentiated diagnostic expertise with testing performed in...
CENTOGENE to Present at the H.C. Wainwright Global Investment Conference
May 19, 2022 06:30 ET
|
Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 19, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the commercial-stage essential biodata life science partner for rare and...
CENTOGENE CEO Kim Stratton to Speak at BIO-Europe Spring® 2022 Conference
March 24, 2022 06:30 ET
|
Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 24, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose,...
CENTOGENE to Announce Fourth Quarter and Fiscal Year 2021 Financial Results on March 30, 2022
March 23, 2022 06:30 ET
|
Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 23, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to...
CENTOGENE Announces Voting Results of Extraordinary General Meeting
February 22, 2022 06:30 ET
|
Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose,...
CENTOGENE Announces CFO Transition and Appointment of Miguel Coego Rios as EVP Finance & Legal and Interim CFO
February 08, 2022 06:30 ET
|
Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose,...
CENTOGENE Announces Nomination of Kim Stratton as Chief Executive Officer
February 01, 2022 05:30 ET
|
Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose,...
CENTOGENE Announces Nomination of Andreas Busch to Supervisory Board
February 01, 2022 05:30 ET
|
Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose,...
CENTOGENE Announces USD 62 Million Aggregate Equity and Debt Financings to Support Growth Plan
February 01, 2022 05:30 ET
|
Centogene NV
Enables refocusing on core business of delivering valuable, data-driven insights to patients, and pharmaceutical companies globallyEUR 15 million private placement from leading growth investors and a...
CENTOGENE’s CentoCloud® Set to Revolutionize Rare Disease Diagnostics With Decentralized SaaS Platform for Laboratories Around the World
January 04, 2022 08:00 ET
|
Centogene NV
The CentoCloud solution is a cloud-based Software as a Service (SaaS) platform that enables laboratories around the world to analyze, interpret, and report genomic variants, and will be able to...